The first-line combination of amivantamab-vmjw plus lazertinib extended OS compared with osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer, according to data from the ...
Black Diamond Therapeutics presents a compelling investment opportunity with strong potential, balanced by inherent biotech ...
This evaluation reviews the evidence for osimertinib for treating NSCLC after complete tumour resection. It also reviews new evidence collected as part of the managed access agreement, which includes ...
Hosted on MSN2mon
Daily pill for lung cancer to be made routinely available on the NHSEGFR mutations, which are prevalent in cases of NSCLC, lead to abnormal cell growth, but Osimertinib works by targeting these mutated cells, aiming to prevent the cancer's return post-surgery.
In LAURA Phase III trial, TAGRISSO continues to demonstrate improved overall survival trend in unresectable, Stage III setting SAVANNAH and ORCHARD Phase II trials show the addition of savolitinib ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback